Fairmount Funds Management’s RayzeBio RYZB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-1,245,929
Closed -$77.5M – 17
2023
Q4
$77.5M Buy
1,245,929
+24,025
+2% +$597K 8.18% 5
2023
Q3
$27.1M Buy
+1,221,904
New +$25.7M 3.26% 12

Fairmount Funds Management's RYZB Position: Q1 2024 in Review

Fairmount Funds Management sold out of RayzeBio (RYZB) in Q1 2024, closing a stake of 1,245,929 shares — an estimated $77.5M sold.

Fairmount Funds Management first reported a position in RYZB in Q3 2023 and held it in 2 quarters. The position peaked at $77.5M in Q4 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.

  • Fairmount Funds Management reported no remaining RayzeBio position as of Q1 2024 after selling out during the quarter.
  • Fairmount Funds Management sold 1,245,929 RayzeBio shares in Q1 2024, an estimated $77.5M.
  • Fairmount Funds Management first reported a position in RayzeBio in Q3 2023 and held it in 2 quarters.
  • Fairmount Funds Management's RayzeBio position peaked at $77.5M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held RayzeBio as of Q1 2024.

Based on Fairmount Funds Management's 13F filing for Q1 2024, filed 15 May 2024.